Patents by Inventor Dominique Dernis

Dominique Dernis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoglobulin G concentrate for therapeutic use and process for producing said concentrate
    Patent number: 6069236
    Abstract: The invention relates to a plasma derived immunoglobulin G concentrate and to the process for producing said concentrate. The process comprises a series of chromatographic separations but no ethanol precipitation. The process also includes a viral inactivation treatment. The invention relates to the immunoglobulin G concentrate obtained by said process which is of therapeutic quality suitable for any use especially for intraveinous injection.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: May 30, 2000
    Assignee: Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord
    Inventors: Miryana Burnouf-Radosevich, Dominique Dernis, Patrick Bonneel, Thierry Burnouf
  • Process for the preparation of purified albumin solutions
    Patent number: 6022954
    Abstract: The invention relates to a process for preparing purified albumin from a human or animal physiological solution, such as a plasma or a plasma fraction. The process includes a process of delipidation using an anionic detergent and two chromatographic separation stages using ion-exchange resin. By applying the process according to the invention, it is possible to obtain an albumin solution of great purity, that is stable and suitable for therapeutic use.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: February 8, 2000
    Assignee: Centre Regional de Transfusion Sanguine de Lille
    Inventors: Dominique Dernis, Thierry Burnouf
  • Process for preparing a human thrombin concentrate intended for therapeutic use
    Patent number: 5304372
    Abstract: Process for preparing a human thrombin concentrate from the PPSB fraction of plasma that does not involve any addition of factors of animal origin to induce activation of the prothrombin to produce thrombin, and which includes a viral inactivation step using solvent-detergent and purification by cation exchange chromatography. The choice of a protective medium ensures the high specific activity of the final product. The thrombin concentrate obtained using this process is intended for therapeutic use, either alone, to serve as a local hemostatic agent, or in combination with a fibrinogen concentrate to form biological glue.
    Type: Grant
    Filed: July 17, 1992
    Date of Patent: April 19, 1994
    Assignee: Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord
    Inventors: Catherine Michalski, Dominique Dernis
  • Blood coagulation factor XI concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
    Patent number: 5252217
    Abstract: The invention relates to a human Factor XI concentrate having high specific activity prepared using a process comprising a filtration-adsorption step and a single step of chromatography on cation exchange resin.The concentrate obtained is perfectly suitable for therapeutic use in replacement therapy in cases of Factor XI deficiency.
    Type: Grant
    Filed: May 7, 1992
    Date of Patent: October 12, 1993
    Assignee: Association pour l'Essor de la Transfusion Sanguine dans la Region du Nord
    Inventors: Miryana Burnouf-Radosevich, Dominique Dernis